Drug Profile


Alternative Names: Type I interferon receptor

Latest Information Update: 28 Jan 2005

Price : $50

At a glance

  • Originator Merck Serono; Weizmann Institute of Science; Yeda
  • Developer Merck Serono; Yeda
  • Class
  • Mechanism of Action Interferon alpha inhibitors; Interferon beta inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Autoimmune disorders; Multiple sclerosis

Most Recent Events

  • 29 Mar 2004 Discontinued - Phase-I for Autoimmune disorders in Israel (unspecified route)
  • 29 Mar 2004 Discontinued - Phase-II for Multiple sclerosis in Switzerland (unspecified route)
  • 29 Mar 2004 Discontinued - Preclinical for Autoimmune disorders in Switzerland (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top